{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-21-134411","form_type":"8-K","ticker":"CVRX","cik":"0001235912","company_name":"CVRx, Inc.","filed_at":"2021-11-04T23:59:59+00:00","discovered_at":"2026-05-14T18:04:11.845631+00:00","generated_at":"2026-06-28T12:38:41.894753+00:00","sec_items":["1.02","2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"CVRx reports Q3 revenue $3.4M (+241% YoY); repays $20M loan","bullets":["Q3 revenue $3.4M (241% YoY increase); U.S. HF revenue $2.5M vs $140K prior year.","Net loss $6.1M ($0.30/share) vs $3.2M ($9.56/share) prior year; cash $170.9M.","Fully repaid $20M Horizon loan on Nov 3, including fees total $21.3M.","FY2021 guidance: revenue $13.3-13.9M; Q4 revenue expected $3.9-4.5M.","Filed three PMA Supplement submissions for Barostim platform; FDA approval expected H1 2022."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-21-134411","json":"https://secwatch.observer/filing/0001104659-21-134411.json","markdown":"https://secwatch.observer/filing/0001104659-21-134411.md","text":"https://secwatch.observer/filing/0001104659-21-134411.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1235912/000110465921134411/0001104659-21-134411-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1235912/000110465921134411/tm2131665d1_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-28T12:38:41.894753+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}